JAC Advance Access originally published online on February 6, 2008
Journal of Antimicrobial Chemotherapy 2008 61(4):880-883; doi:10.1093/jac/dkn028
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
Efficacy of a new formulation of amphotericin B in a murine model of disseminated infection by Candida glabrata
1 Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain 2 Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense, Madrid, Spain
Received 10 September 2007; returned 9 October 2007; revised 7 December 2007; accepted 8 January 2008
* Corresponding author. Tel: +34-977-759359; Fax: +34-977-759322; E-mail: josep.guarro{at}urv.cat
Objectives: Amphotericin B poly-aggregates are a new formulation of amphotericin B, which can be obtained cheaply. In this study, we tested the efficacy of this new formulation for treating a disseminated infection by Candida glabrata in a murine model.
Methods: Mice were rendered neutropenic by intraperitoneal cyclophosphamide and intravenous 5-fluorouracil administration and infected intravenously with 2 x 108 cfu of C. glabrata. The efficacy of the new formulation of amphotericin B was evaluated by survival and tissue burden studies. The experiments were repeated using three different clinical strains of C. glabrata.
Results and conclusions: Amphotericin B poly-aggregates showed an efficacy similar to that of amphotericin B deoxycholate and liposomal amphotericin B in the treatment of a disseminated murine infection by C. glabrata.
Keywords: candidiasis , animal models , poly-aggregates